Share on StockTwits

Shares of Bristol-Myers Squibb (NYSE:BMY) have earned a consensus rating of “Hold” from the eighteen analysts that are presently covering the stock, AnalystRatings.Net reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $51.83.

A number of research firms have recently commented on BMY. Analysts at TheStreet reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note on Wednesday, August 27th. They noted that the move was a valuation call. Separately, analysts at Deutsche Bank initiated coverage on shares of Bristol-Myers Squibb in a research note on Wednesday, August 27th. They set a “hold” rating and a $52.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at Jefferies Group raised their price target on shares of Bristol-Myers Squibb from $43.50 to $45.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock.

Shares of Bristol-Myers Squibb (NYSE:BMY) opened at 50.65 on Thursday. Bristol-Myers Squibb has a 52 week low of $41.32 and a 52 week high of $57.49. The stock has a 50-day moving average of $49.67 and a 200-day moving average of $50.4. The company has a market cap of $83.973 billion and a P/E ratio of 31.39.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings data on Thursday, July 24th. The company reported $0.48 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.04. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.85 billion. During the same quarter in the previous year, the company posted $0.44 earnings per share. The company’s revenue for the quarter was down 3.9% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb will post $1.81 EPS for the current fiscal year.

In other Bristol-Myers Squibb news, SVP Autenried Paul Von sold 20,000 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $49.89, for a total value of $997,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.

Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with Analyst Ratings Network's FREE daily email newsletter.